Search Within

Eli Louis Diamond

  1. "Kseniya Petrova-Drus"
Formats
  1. Meeting Abstract (9)
  2. Journal Article (6)
  3. Correspondence (1)
  4. Research Letter (1)
Groups
  1. Department of Pathology and Laboratory Medicine (17)
  2. Center for Hematologic Malignancies (15)
  3. Department of Medicine (15)
  4. Hematologic Malignancies, Division of (15)
  5. Executive Committee, Center for Hematologic Malignancies (14)
  6. GSK Faculty (14)

More Groups

People
  1. Kseniya Petrova-Drus (17)
  2. Benjamin Durham (16)
  3. Mariko Yabe (15)
  4. Omar Abdel-Wahab (14)
  5. Mario Lacouture (10)
  6. Veronica Rotemberg (10)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (8)
  4. 2022 (3)
  5. 2020 (3)
  6. 2019 (1)
Publications
  1. Blood (4)
  2. Pediatric Blood and Cancer (4)
  3. British Journal of Haematology (2)
  4. Leukemia (2)
  5. Clinical Cancer Research (1)
  6. Journal of Clinical Oncology (1)

More Publications

Publishers
  1. American Society of Hematology (4)
  2. Nature Publishing Group (4)
  3. Wiley Periodicals, Inc (4)
  4. John Wiley & Sons (2)
  5. American Association for Cancer Research (1)
  6. American Society of Clinical Oncology (1)

More Publishers

Results (17)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasms
    Correspondence

    Salmon-Divon, M.; Meyuchas, R.; Shpilberg, O.; Okon, E.; Benhamida, J.; Yabe, M.; Petrova-Drus, K.; Zvida-Bloch, T.; Basood, M.; Mazor, R.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy
    Journal Article

    Friedman, J. S.; Durham, B. H.; Reiner, A. S.; Yabe, M.; Petrova-Drus, K.; Dogan, A.; Pulitzer, M.; Busam, K. J.; Francis, J. H.; Rampal, R. K.; more...
    British Journal of Haematology (2024)

    Fulltext@MSK | Save
  • Outcomes with MEK inhibitor therapy among adults with Langerhans cell histiocytosis (LCH): A multi-institutional study from the Adult LCH Working Group for the Histiocyte Society
    Meeting Abstract

    Goyal, G.; Acosta Medina, A. A.; Cao, X.; Bossert, D.; Matthew, P. C.; Makras, P.; Abdel-Wahab, O.; Abeykoon, J. P.; Amerikanou, R.; Bach, C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Deciphering the epigenetic landscape in histiocytic neoplasms
    Meeting Abstract

    Salmon-Divon, M.; Meyuchas, R.; Benhamida, J.; Shpilberg, O.; Mazor, R. D.; Yabe, M.; Petrova-drus, K.; Abdel-Wahab, O.; Diamond, E. L.; Hershkovitz-Rokah, O.
    Blood (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of single-agent cobimetinib for adults with histiocytic neoplasms
    Meeting Abstract

    Diamond, E. L.; Durham, B.; Dogan, A.; Yabe, M.; Petrova-Drus, K.; Rampal, R. K.; Ulaner, G.; Lacouture, M.; Rotemberg, V.; Covey, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms
    Journal Article

    Reiner, A. S.; Durham, B. H.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Lacouture, M. E.; Rotemberg, V.; Abdel-Wahab, O.; Panageas, K. S.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • CSF1R inhibition for histiocytic neoplasm with CBL mutations refractory to MEK1/2 inhibition
    Research Letter

    Diamond, E. L.; Francis, J. H.; Lacouture, M. E.; Rotemberg, V.; Yabe, M.; Petrova-Drus, K.; Ulaner, G. A.; Reddy, R.; Abdel-Wahab, O.; Durham, B. H.
    Leukemia (2023)

    Fulltext@MSK | Save
  • Overcoming barriers to tumor genomic profiling through direct-to-patient outreach
    Journal Article

    Doe-Tetteh, S. A.; Camp, S. Y.; Reales, D.; Crowdis, J.; Noronha, A. M.; Wolff, B.; Alano, T.; Galle, J.; Selcuklu, S. D.; Viale, A.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including novel treatment with the ERK inhibitor ulixertinib
    Meeting Abstract

    Diamond, E. L.; Rosenblum, M.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Lacouture, M. E.; Rotemberg, V. M.; Hatzoglou, V.; Young, R.; more...
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • A multinational series of 26 patients with mixed histiocytic neoplasms highlighting a diverse mutational landscape and superior efficacy of targeted therapies
    Meeting Abstract

    Diamond, E. L.; Durham, B. H.; Reiner, A. S.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Ulaner, G. A.; Reddy, R.; Lacouture, M. E.; more...
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save